IntiQuan enhances PLG’s portfolio with advanced dose-response evaluations and proactive safety assessments. Credit: IM Imagery/Shutterstock. ProductLife Group (PLG) has announced the acquisition of IntiQuan, a
Illuccix is used for PET imaging to detect PSMA-positive lesions in male prostate cancer patients. Credit: Korawat photo shoot/Shutterstock. Health Canada has expanded the approved
OKI-219 is in Phase I trials for solid tumours. Credit: Nemes Laszlo/Shutterstock. OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, with
The therapy modifies patients’ T cells to carry an anti-CD7 CAR and re-administers them. Credit: Kateryna Kon/Shutterstock. Singapore’s National University Health System (NUHS) has announced
CAD is a rare blood disorder where B cells produce antibodies that destroy red blood cells. Credit: Siwakorn TH via Shutterstock. Recordati has reached an
mAbxience will create oncology biosimilars using its cGMP-certified plants in Spain and Argentina. Credit: Lightspring via Shutterstock. Teva Pharmaceuticals International and mAbxience have entered into
BMS’ Opdivo is said to be the only PD-1 inhibitor to demonstrate an advantage over chemotherapy, both presurgery and in a perioperative setting. Credit: HJBC
The funding will enable Aralez Bio to enhance cGMP production capabilities by leveraging an advanced technology. Credit: National Resilience/Business Wire. National Resilience’s subsidiary Resilience Government
The agreement focuses on advancing Talem Therapeutics’ lead bispecific antibody, TATX-20, for treating hypoxic solid tumours. Credit: Sebastian Kaulitzki via Shutterstock. ImmunoPrecise Antibodies, an AI-driven
Vevizye’s effectiveness in treating DED was confirmed by two placebo-controlled trials. Credit: fizkes via Shutterstock. Novaliq and Laboratoires Théa have announced approval from the European